BioSpace News Archive

Bright Minds Biosciences today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference as follows: Date: Wednesday, December 8, 2021 Time: 3:00PM.

Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced the formation of its Scientific Advisory Board for rare metabolic diseases.

Bavarian Nordic A/S a fully integrated vaccines company, formally announces its commitment to initiate a Phase 3 clinical trial of its RSV vaccine candidate, MVA-BN® RSV.

Spago Nanomedical AB announced it has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad.

OKYO Pharma Limited, the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that working with Ora, Inc., a world-class ophthalmic clinical development partner, it is currently anticipating the filing of an IND in Q3 2022 for OK-101 in the treatment of dry eye disease.

Aran Biomedical has expanded their weaving capabilities to include the condensing of high-density woven fabric.

The 2nd R&D Day event of IMPACT Therapeutics successfully took place in Shanghai on December 3rd.

XPhyto Therapeutics Corp. is pleased to announce that the acquisition of 3a-diagnostics GmbH, first announced July 20, 2021, is now complete.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that the first patient has been dosed in a Phase 1b/2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in combination with elranatamab (PF-06863135) Pfizer’s investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.